Debt (Tables)

9 Months Ended

Sep. 30, 2026

Below is a summary of the Company's repurchase facilities and revolving credit facilities - commercial mortgage loans ("Repo and Revolving Credit Facilities"), Mortgage note payable, Other financings and Unsecured debt as of September 30, 2026 and December 31, 2025 (dollars in thousands):


	September 30, 2026
Repo and revolving credit facilities - commercial mortgage loans(2):	Capacity		Amount Outstanding		Interest Expense(1)		Ending Weighted Average Interest Rate		Term Maturity
JPM Repo Facility(3)	$	750,000	$	328,140	$	25,440	6.11	%	07/2027

Atlas Repo Facility	350,000		76,347		7,363		6.44	%	01/2027
WF Repo Facility(4)	250,000		23,191		2,388		5.20	%	10/2027
Barclays Revolver Facility(5)	—		—		74		N/A		N/A
Barclays Repo Facility(6)	500,000		25,045		2,117		5.36	%	03/2028
MS Repo Facility(7)	150,000		28,055		287		5.35	%	05/2029
GS Repo Facility(8)	250,000		—		—		N/A		07/2028
BAML WH Line of Credit(10)	450,000		50,720		1,671		4.98	%	06/2027
Fifth Third WH Line of Credit(10)	400,000		152,980		1,095		5.20	%	07/2027
Fifth Third Line of Credit(11)	125,000		—		1,100		N/A		03/2027
JPM WH Line of Credit(12)	700,000		89,560		1,929		5.26	%	01/2027
PNC WH Line of Credit(13)	500,000		63,863		1,190		5.21	%	12/2026
ASAP WH Line of Credit(14)	100,000		—		—		N/A		N/A
Total/Weighted average	$	4,525,000	$	837,901	$	44,654	5.68	%
Mortgage note payable:
Debt related to our REO(15)	N/A		$	24,186	$	1,136	6.07	%	04/2029
Other financings:
Other financings(16)	N/A		$	12,865	$	585	6.00	%	07/2028
Unsecured Debt
Senior Notes(17)(18)	N/A		$	107,000	$	7,150	Various(17)(18)		Various(17)(18)
Junior Note I(19)	N/A		17,500		1,022		7.60	%	10/2035
Junior Note II(19)	N/A		40,000		2,230		7.46	%	12/2035
Junior Note III(20)	N/A		—		1,340		—	%	09/2036
Total/Weighted average	N/A		$	164,500	$	11,742	7.91	%

________________________

See notes below.


	December 31, 2025
Repo and revolving credit facilities - commercial mortgage loans(2):	Capacity		Amount Outstanding		Interest Expense(1)		Ending Weighted Average Interest Rate		Term Maturity
JPM Repo Facility(3)	$	500,000	$	439,408	$	18,107	6.04	%	07/2026
Atlas Repo Facility	350,000		150,744		10,598		6.35	%	01/2027
WF Repo Facility(4)	250,000		75,172		1,749		5.22	%	10/2027
Barclays Revolver Facility(5)	100,000		—		438		N/A		09/2026
Barclays Repo Facility(6)	500,000		82,602		8,889		5.59%		03/2028
Churchill Repo Facility(9)	—		—		555		N/A		N/A
BAML WH Line of Credit(10)	500,000		9,399		1,210		5.17%		06/2026
Fifth Third WH Line of Credit(10)	400,000		44,007		3,169		5.02%		07/2026
Fifth Third Line of Credit(11)	100,000		15,000		1,265		6.53	%	08/2026
JPM WH Line of Credit(12)	700,000		222,831		5,892		5.04	%	01/2026
PNC WH Line of Credit(13)	500,000		47,924		1,628		4.99	%	12/2026
ASAP WH Line of Credit(14)	100,000		—		—		N/A		N/A
Total/Weighted average	$	4,000,000	$	1,087,087	$	53,500	5.70	%
Mortgage note payable:
Debt related to our REO(15)	N/A		$	23,998	$	1,783	6.87	%	10/2026
Other financings:
Other financings(16)	N/A		$	12,865	$	783	6.00	%	07/2028
Unsecured Debt
Senior Notes(17)(18)	N/A		$	107,000	$	6,158	Various(17)(18)		Various(17)(18)
Junior Note I(19)	N/A		17,500		1,458		7.60	%	10/2035
Junior Note II(19)	N/A		40,000		3,195		7.28	%	12/2035
Junior Note III(20)	N/A		25,000		1,997		7.28	%	09/2036
Total/Weighted average	N/A		$	189,500	$	12,808	7.81	%

________________________

(1) Represents year to date expense and includes amortization of deferred financing costs.

(2) The Company may pledge one or more mortgage loans to the financing entity in exchange for funds typically at an advance rate of between 60% to 75% of the principal amount of the mortgage loan being pledged. These loans are all floating rate at the Secured Overnight Financing Rate ("SOFR") plus an applicable spread. Additionally, the Repo and Revolving Credit Facilities generally provide that in the event of a decrease in the value of the Company's collateral, the lenders can demand additional collateral. As of both September 30, 2026 and December 31, 2025, the Company was in compliance with all debt covenants.

(3) On May 7, 2026, the Company extended the maturity date to July 27, 2027. There is one one-year extension option remaining.

(4) There are three one-year extension options.

(5) On September 19, 2026, the Company terminated the Barclays Revolver Facility.

(6) There is one one-year extension option.

(7) There are two one-year extension options.

(8) On July 30, 2026, the Company entered into a master repurchase agreement ("MRA") with Goldman Sachs Bank USA, with a maximum facility amount of $250.0 million and an initial two-year term with one one-year extension option.

(9) On October 21, 2025, the Company terminated the Churchill MRA.

(10) Collateralized by a first lien on the Company’s interest in the mortgage loans that it originates. Advances cannot exceed 100% of the principal amounts of the mortgage loans originated by the Company and must be repaid at the earlier of the sale or other disposition of the mortgage loans or at the expiration date of the Line of Credit.

(11) Operating line that is secured by an equity interest in NewPoint Real Estate Capital LLC ("NPREC").

(12) On January 31, 2026, the Company extended the maturity date to January 29, 2027.

(13) Collateralized by a first lien on the Company’s interest in the mortgage loans that it originates.

(14) The Company has a $100.0 million ASAP agreement with Fannie Mae providing us with a warehousing credit facility for mortgage loans that are to be sold to Fannie Mae and serviced under the Fannie Mae DUS program. The ASAP agreement is not a committed line, has no expiration date and bears interest at SOFR + 1.50%, with a 0.25% SOFR floor.

(15) Relates to a mortgage note payable in Jeffersonville JV, a consolidated joint venture. The loan has a principal amount of $113.6 million of which $89.4 million of the loan is owned by the Company and was eliminated in our consolidated financial statements (see Note 8 - Real Estate Owned). On April 9, 2026, the Company refinanced the mortgage note, upsized the capacity and extended the maturity date to April 9, 2029 for the Company and the affiliated fund (see Note 18 - Related Party Transactions and Arrangements).

(16) Comprised of one note-on-note financing via a participation agreement. From inception of the loan, the Company's outstanding loan could increase as a result of future fundings, leading to an increase in amount outstanding via the participation agreement. The contractual maturity date of this loan is July 2028.

(17) During the second quarter of 2025, the Company issued $82.0 million of 8.25% fixed-rate senior unsecured notes. These notes mature on April 30, 2030.

(18) During the second quarter of 2025, the Company issued $25.0 million of floating-rate senior unsecured notes. As of September 30, 2026, the interest rate on these notes was SOFR + 4.00%. These notes mature on April 25, 2028.

(19) The notes are currently redeemable, in whole or in part, without penalty, at the Company’s option. Interest paid on unsecured Junior Notes I and II totaled $0.8 million and $2.9 million for the three and nine months ended September 30, 2026, respectively.

(20) During the third quarter of 2026, the Company repurchased and subsequently cancelled the Junior Note III, recognizing a gain of $1.7 million in Realized gain/loss on extinguishment of debt in the consolidated statement of operations as of September 30, 2026. Interest paid on Junior Note III totaled $0.7 million and $1.7 million for the three and nine months ended September 30, 2026, respectively.

Schedule of Repurchase Agreements

Below is a summary of the Company's MRAs which were included in Repurchase agreements - real estate securities in the Company's consolidated balance sheets as of September 30, 2026 and December 31, 2025 (dollars in thousands):


	September 30, 2026
Counterparty	Amount Outstanding		Interest Expense		Collateral Pledged(1)		Weighted Average Interest Rate		Weighted Average Days to Maturity
JP Morgan Securities LLC	$	—	$	738	$	—	—	%	0

Barclays Capital Inc.	—		773		—		—	%	0
Lucid Prime Fund	—		1,438		—		—	%	0
Santander Securities	39,489		2,844		49,014		4.70	%	13
Total/Weighted Average	$	39,489	$	5,793	$	49,014	4.70	%	13

________________________

See note below


	December 31, 2025
Counterparty	Amount Outstanding		Interest Expense		Collateral Pledged(1)		Weighted Average Interest Rate		Weighted Average Days to Maturity
JP Morgan Securities LLC	$	7,856	$	1,278	$	9,254	4.63	%	29
Wells Fargo Securities, LLC	—		2,288		—		—	%	0
Barclays Capital Inc.	25,044		1,510		31,386		4.83	%	25
Lucid Prime Fund	54,718		1,644		65,324		4.67	%	15
Santander Securities	99,753		1,294		119,880		4.60	%	14
Total/Weighted Average	$	187,371	$	8,014	$	225,844	4.65	%	16

________________________

(1) Includes $49.0 million and $74.2 million of CMBS bonds, held by the Company, which is eliminated through consolidation of the related CLO's on the Company's consolidated balance sheets as of September 30, 2026 and December 31, 2025, respectively.

Schedule of Collateralized Loan Obligations by Tranche

The following table represents the terms of the notes issued by 2023-FL10 Issuer, 2024-FL11 Issuer, 2025-FL12 Issuer and 2026-FL13 Issuer (collectively the “CLOs”) as of September 30, 2026 and December 31, 2025:


	September 30, 2026
CLO Facility	Number of Loans in pool(1)	Benchmark interest rate	Weighted Average Spread		Par Value		Par Value Outstanding(2)		Principal Balance of Collateralized Mortgage Assets		Maturity Dates
2023-FL10 Issuer	22	AVG SOFR	3.14	%	717,243		267,198		446,227		9/15/2035
2024-FL11 Issuer	41	Term SOFR	1.99	%	886,176		886,176		1,023,948		7/15/2039
2025-FL12 Issuer	65	Term SOFR	1.61	%	947,189		947,189		1,075,998		4/17/2043
2026-FL13 Issuer	45	Term SOFR	1.76	%	778,094		778,094		871,736		10/18/2043
					$	3,328,702	$	2,878,657	$	3,417,909

	December 31, 2025
CLO Facility	Number of Loans in pool(1)	Benchmark interest rate	Weighted Average Spread		Par Value		Par Value Outstanding(2)		Principal Balance of Collateralized Mortgage Assets		Maturity Dates
2022-FL8 Issuer	21	AVG SOFR	2.07	%	960,000		370,348		609,074		2/15/2037
2023-FL10 Issuer	32	Term SOFR	2.68	%	717,243		553,214		715,694		9/15/2035
2024-FL11 Issuer	38	Term SOFR	1.99	%	886,176		886,176		1,024,380		7/15/2039
2025-FL12 Issuer	50	Term SOFR	1.67	%	947,189		947,189		1,046,909		4/17/2043
					$	3,510,608	$	2,756,927	$	3,396,057

________________________

(1) Loan assets may be pledged towards one or multiple CLO pools.

(2) Excludes $277.0 million and $366.1 million of CLO notes held by the Company, which are eliminated in Collateralized loan obligations in the consolidated balance sheet as of September 30, 2026 and December 31, 2025, respectively.

Schedule of Collateralized Loan Obligations

The below table reflects the total assets and liabilities of the Company's outstanding CLOs. The CLOs are considered VIEs and are consolidated into the Company's consolidated financial statements as of September 30, 2026 and December 31, 2025 as the Company is the primary beneficiary of the VIE. The Company is the primary beneficiary of the CLOs because (i) the Company has the power to direct the activities that most significantly affect the VIE’s economic performance and (ii) the right to receive benefits from the VIEs or the obligation to absorb losses of the VIEs that could be significant to the VIE. The VIEs are non-recourse to the Company.


	September 30, 2026		December 31, 2025
Assets (dollars in thousands)
Cash and cash equivalents(1)	$	12,386	$	51,153
Commercial mortgage loans, held for investment, net(2)	3,234,613		3,317,040
Accrued interest receivable	15,640		18,302
Total Assets	$	3,262,639	$	3,386,495

Liabilities (dollars in thousands)
Notes payable(3)(4)	$	3,155,697	$	3,123,046
Accrued interest payable	8,267		8,857
Total Liabilities	$	3,163,964	$	3,131,903

________________________

(1) Includes $11.8 million and $50.5 million of cash held by the servicer related to CLO loan payoffs as of September 30, 2026 and December 31, 2025, respectively.

(2) The balance is presented net of allowance for credit losses of $17.3 million and $15.4 million as of September 30, 2026 and December 31, 2025, respectively.

(3) Includes $277.0 million and $366.1 million of CLO notes, held by the Company, which are eliminated in Collateralized loan obligations of the consolidated balance sheets as of September 30, 2026 and December 31, 2025, respectively.

(4) The balance is presented net of deferred financing cost and discount of $21.8 million and $21.3 million as of September 30, 2026 and December 31, 2025, respectively. The deferred financing costs are amortized over the expected lifetime of each CLO.

The following table presents the assets and liabilities of the consolidated CMBS trust (dollars in thousands):


Assets:	September 30, 2026
Commercial mortgage loans, at fair value	$	518,364
Accrued interest receivable	2,895
Consolidated variable interest entities assets, at fair value	$	521,259
Liabilities:
Commercial mortgage-backed securities, at fair value	$	490,690
Accrued interest payable	2,703
Consolidated variable interest entities liabilities, at fair value	$	493,393

________________________

In the prior year, the Company did not consolidate any CMBS trust entities.

The following table presents the change in net assets of the consolidated variable interest entity (dollars in thousands):


	Three Months Ended September 30, 2026		Nine Months Ended September 30, 2026
Interest income	$	8,877	$	12,834
Interest expense	(8,022)		(11,683)
Unrealized gain/(loss)	269		269
Change in net assets of consolidated variable interest entity	$	1,124	$	1,420

________________________

In the prior year, the Company did not consolidate any CMBS trust entities.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details